Yazar "Yerlikaya, Halis" seçeneğine göre listele
Listeleniyor 1 - 14 / 14
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Are Syrian refugee breast cancer patients diagnosed at advanced stage and do they have treatment delays?(Future Medicine Ltd, 2023) Karhan, Ogur; Secmeler, Saban; Sezgin, Yasin; Ileri, Serdar; Yerlikaya, HalisAim: To compare the clinicopathological features and time to reach treatment of patients with breast cancer among Syrian refugees (SRs) and Turkish citizens (TCs). Methods: Retrospective data from 2014 to 2021 were extracted from the hospital database. Student's t-test, Mann-Whitney U test and chi 2 test were used to compare the two groups. Results: Data of 88 SR and 402 TC patients were analyzed. The mean age was 45 years for SRs and 50 years for TCs. Breast cancer subtypes were similar in both groups. The de novo metastatic ratio was 23% in SRs and 21.3% in TCs and the time to reach treatment was similar between the two groups. Conclusion: Provided the absence of any obstacle in the healthcare system, SRs are diagnosed and treated like the citizens of their host nation. Tweetable abstractPatients with breast cancer among Syrian refugees are younger but are not diagnosed and treated later than Turkish citizens. #Syrian #refugees #TreatmentDelay #BreastCancerÖğe The Clinical and Demographic Characteristics of Our Cases with Primary Bone Tumors and Soft Tissue Tumors(Akad Doktorlar Yayinevi, 2016) Oruc, Zeynep; Kaplan, Muhammet A.; Yerlikaya, Halis; Celik, M. Ali; Oruc, Idris; Urakci, Zuhat; Kucukoner, MehmetThe current study aimed to investigate the clinical and demographic characteristics of the patients with sarcoma who were treated and followed-up in Dicle University Medical Oncology Department. We retrospectively investigated the medical records of 547 patients who were diagnosed with sarcoma in the Dicle University School of Medicine, Department of Medical Oncology, between 2007 and 2015. When we considered the total number of patients (total 23,264) admitted to our center between 2007 and 2015, the rate of our patients with sarcoma was found to be 2.3% of this total number. Primary bone tumor and soft tissue sarcoma were determined in 32% (n=172) and 68% (n=375) of the patients, respectively. The most frequent histological type was osteosarcoma. The age, location of the primary tumor, adjuvant chemotherapy, location of relapse (local, metastatic), history of smoking, and comorbid diseases showed statistically significant differences between two groups. The overall survival and progression-free survival also did not differ significantly between the primary bone tumors and soft tissue tumors (p=0.65). The rate of our patients with sarcoma was 2.3% of the total number of patients (total 23,264) admitted to our center. This rate is higher than that in the literature. It is hard to interpret the results of the study, however it has been confirmed that the soft tissue sarcomas and primary bone tumors differ with regard to the age at diagnosis, location of tumor, location of relapse, prevalence of adjuvant chemotherapy and risk factors.Öğe Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study(Karger, 2019) Kaplan, Muhammet Ali; Ozaydin, Sukru; Yerlikaya, Halis; Karaagac, Mustafa; Gumus, Mahmut; Cil, Timucin; Arslan, Ulku YalcintasBackground: Colorectal cancer (CRC) is a rare disease amongst children and adolescents. Previous studies have reported a number of differences between children/adolescents, young adults, and adult patients with CRC. However, none of these studies compared these age groups according to their clinicopathologic and prognostic characteristics. In the current study, we compare these three age groups. Methods:A total of 173 (1.1% of 15,654 patients) young CRC patients (<= 25 years) were included in the study. As a control group, 237 adult CRC patients (>25 years) were also included. Patients were divided into three age groups: child/adolescent (10-19 years), young adult (20-25 years), and adult (>25 years). Results: Statistical differences amongst the three groups in terms of gender (p = 0.446), family history (p = 0.578), symptoms of presentation (p = 0.306), and interval between initiation of symptoms and diagnosis (p = 0.710) could not be demonstrated. Whilst abdominal pain (p < 0.001) and vomiting (p = 0.002) were less common in young adults than in other groups, rectal bleeding and changes in bowel habits were relatively less common in adolescents than in other groups. Rectal localisation (p = 0.035), mucinous adenocarcinoma (p < 0.001), and a poorly differentiated histologic subtype (p < 0.001) were less common in the adult group than in other groups. The percentage of patients with metastasis and sites of metastasis (e.g., peritoneum and lung) differed between groups. The median overall survival was 32.6 months in the adolescent group, 57.8 months in the young adult group and was not reached in the adult group (p = 0.022). The median event-free survival of the adolescent, young adult, and adult groups was 29.0, 29.9, and 61.6 months, respectively (p = 0.003). Conclusions: CRC patients of different age groups present different clinicopathologic and prognostic characteristics. Clinicians should be aware of and manage the disease according to these differences.Öğe Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy(Future Medicine Ltd, 2022) Ebinc, Senar; Oruc, Zeynep; Sezgin, Yasin; Karhan, Ogur; Bilen, Erkan; Yerlikaya, Halis; Kalkan, ZiyaPlain language summary HER2 is an important and targetable molecule in breast cancer. In the early stages of breast cancer, a treatment modality called neoadjuvant therapy, which now includes anti-HER2 therapies, is administered before surgery in order to achieve disease regression and make the patient suitable for a more minor operation. In breast cancer, HER2 status may be positive in the initial biopsy specimen and negative in the surgical specimen. HER2 status plays an important role in treatment decisions. In this study, we investigated the factors causing HER2 status to change in early-stage breast cancer. This study has a retrospective design and includes 400 female patients with early-stage breast cancer. The results of the study identified the factors causing HER2 status to change to negative as receipt of neoadjuvant therapy, small tumor size and younger age. Objective: The rates of and the factors influencing HER2 discordance in patients receiving neoadjuvant therapy for breast cancer are investigated. Methods: This study retrospectively examines the rates of HER2 and hormone receptor discordance between the biopsy and postoperative resection specimens of 400 female early-stage breast cancer patients. Results: One hundred and thirty-three (33.3%) patients had received neoadjuvant therapy. The rate of HER2 discordance between biopsy and resection specimens was 1.7% in the control group and 5.3% in the neoadjuvant therapy group (p = 0.018). The rate of HER2 discordance was higher in younger patients and in patients with T1 tumors in the neoadjuvant therapy group. Conclusion: Neoadjuvant therapy, age <40 years and smaller tumor size were independent risk factors for HER2 discordance.Öğe The Importance of the Tumor Sidedness and Its Relationship with Other Clinicopathological Features in Patients with Colorectal Cancer(2021) Yerlikaya, Halis; Söğütçü, Nilgün; Yılmaz, Engin Deniz; Laçin, SahinAim: Colorectal cancer (CRC) is one of the most common and mortal diseases and prognostic factors have a crucial role in stratifying patients. We aimed to evaluate the importance of CDX2 expression, serum CEA level, and tumor sidedness in CRC patients. Material and Method: Patients diagnosed with colorectal cancer between September 2014 and December 2019 were included in the study. Serum CEA level, primary tumor bias, CDX2 expression and other demographic characteristics were recorded as variables. All study analyzes were performed using SPSS version 22 statistical software (IBM Corporation). Results: 152 patients with CRC were included, 64 (42.1%) of patients were female and 88 (57.9%) of patients were male, the median age of patients was 55 (range 18–93). The median survival of patients with serum CEA level <3.5ng/ml, and the patients with CEA level >3.5 ng/ml was 35.1 and 26.6 months, respectively, and the difference between groups was a statistically significant (p=0.006). There was a positive correlation between disease stage and serum CEA level, metastatic patients had higher serum CEA level than non-metastatic patients (p=0.009). In terms of tissue CDX2 expression, eleven patients (7.2%) had CDX2 expression negative, 136 (89.5%) of patients had CDX2 expression positive. The difference between OS rates of patients according to CDX2 expression status was not significant (p=0.7). Despite the longer survival of patients with left-sided than right-sided, the difference was not significant, the median OS was 67.6 and 29.7 months, respectively (p=0.3). The median follow-up time was 24.1 months. Conclusion: The serum CEA level was found as a clear prognostic factor for CRC patients. Additionally, CDX2 expression positive and left-sided primary tumors had longer survival as reported in the literature. Also, our patient stratification model based on tumor sidedness and serum CEA level obtained promising outcomes but need to be confirmed by larger and prospective trials.Öğe Is fat mass more effective than body mass index (BMI) to predict toxicity in early breast cancer patients treated with doxorubicin and cyclophosphamide?(Amer Assoc Cancer Research, 2018) Kaplan, Muhammet Ali; Kavak, Hemrin; Urakci, Zuhat; Nas, Necip; Oruc, Zeynep; Yerlikaya, Halis; Akdeniz, Nadiye[Abstract Not Available]Öğe Kolorektal kanserli hastalarda tümör taraflılığının önemi ve diğer klinikopatolojik özelliklerle ilişkisi(Kafkas Üniversitesi, 2021) Söğütçü, Nilgun; Laçin, Şahin; Yerlikaya, Halis; Yılmaz, DenizAmaç: Kolorektal kanser (KRK) en yaygın ve ölümcül hastalıklardan biridir ve hastaların sınıflandırılmasında prognostik faktörler çok önemlidir. Bu çalışmada, KRK hastalarında CDX2 ekspresyonu, serum CEA düzeyi ve tümör taraflılığının önemini değerlendirmeyi amaçladık. Materyal ve Metot: Eylül 2014-Aralık 2019 tarihleri arasında hastalık evresine bakılmaksızın kolorektal kanser tanısı alan hastalar dahil edildi. KRK tanısı primer veya metastatik lezyondan elde edilen patolojik doku bulguları ile doğrulandı. Serum CEA düzeyi, primer tümör taraflılığı (sağ taraf veya sol taraf), CDX2 ekspresyonu ve elde edilen diğer demografik özellikler çalışma değişkeni olarak kaydedildi. Tüm çalışma analizleri SPSS sürüm 22 istatistik yazılımı (IBM Corporation) kullanılarak yapıldı. Bulgular: KRK'lu 152 hasta dahil edildi, 64 hasta (% 42.1) kadın, 88 hasta (% 57.9) erkek, ortalama yaş 55 (18-93 yaş) idi. Serum CEA düzeyi 3.5 ng / ml olan hastalarda ortalama sağkalım sırasıyla 35.1 ve 26.6 aydı ve gruplar arasındaki fark istatistiksel olarak anlamlıydı (p = 0.006). Hastalık evresi ile serum CEA düzeyi arasında pozitif korelasyon vardı, metastatik hastalarda serum CEA düzeyi metastatik olmayan hastalara göre daha yüksekti (p = 0.009). Doku CDX2 ekspresyonu açısından, on bir hastada (% 7.2) CDX2 ekspresyon negatif, 136 hastada (% 89.5) CDX2 ekspresyon pozitif bulundu. CDX2 ekspresyon durumuna göre hastaların OS oranları arasındaki fark anlamlı değildi (p = 0.7). Sol taraflı hastaların sağ taraflılara göre daha uzun süre hayatta kalmasına rağmen, fark anlamlı değildi, medyan OS sırasıyla 67.6 ve 29.7 aydı (p = 0.3). Ortalama takip süresi 24.1 aydı. Sonuç: Serum CEA düzeyi, CRC hastaları için belirgin bir prognostik faktör olarak bulundu. Ek olarak CDX2 ekspresyonu pozitif ve sol taraflı primer tümörlerin literatürde bildirildiği gibi daha uzun sağkalımı vardı. Ayrıca, tümör taraflılığı ve serum CEA düzeyine dayanan hasta sınıflama modelimiz umut verici sonuçlar elde etmiştir, ancak daha büyük ve prospektif çalışmalarla doğrulanması gerekmektedir.Öğe Measuring the knowledge and attitudes of physicians towards patients with HIV/AIDS: study of Anatolian group(Emerald Group Publishing, 2021) Kaya, Şafak; Araç, Eşref; Akgül, Fethiye; Çomoğlu, Şenol; Kaya, Şehmuz; Araç, Songül; Yıldız, Yeşim; Büyüktuna, Seyit Ali; Kayaaslan, Bircan; Parlak, Emine; Baysal, Birol; Karakeçili, Faruk; Balık, Elif Zelal; Akkoç, Ali; Özdemir, Kevser; Kavak, Şeyhmus; Doğan, Suat Ali; Günay, Emrah; Karabela, Şemsi Nur; Cabalak, Mehmet; Çağ, Yasemin; Avcı, Veli; Durdu, Yasemin; Kaya, Zehra; Kılıç, Damla; Yerlikaya, Halis; Tarakçı, Hüseyin; Menteş, Osman; Tartar, Ayşe Sağmak; Köse, Adem; Alakuş, Ömer Faruk; Aktaş, Ulaş; Kömek, Halil; Aksöz, SelçukThis paper aims to determine the knowledge and attitudes of the physicians regarding human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), to emphasize that these patients exist and they will exist in the future and to raise awareness so as to prevent that their rights to treatment are revoked. Design/methodology/approach The survey was conducted via a link sent through an online system. Random physicians from 81 cities of the country were invited to the survey. The survey has 41 questions regarding knowledge and attitudes in total, including epidemiological information such as age, gender and title. Findings A total of 3,107 physicians has voluntarily participated in the study. In total, 2,195 (70.7%) are internal physicians and 912 (29.3%) are surgical physicians among the participant physicians. In total, 1,452 (46.7%) of the participants are specialist physicians, 608 (19.6%) of the participants are practising physician and the rest of it is physician assistants, academicians and dentists, respectively. Originality/value In this study, it has been found out that the physicians have a lack of knowledge on HIV/AIDS and they adopt a discriminatory attitude towards HIV-positive persons. HIV-positive patients who are exposed to discrimination and scared of being uncovered refrain from applying to hospitals for treatment, which puts public health into jeopardy due to the high viral load and these patients are faced with difficulties in coping with both medical and emotional load of the disease.Öğe Meme kanserli hastalarda Pet - BT ile tümör özellikleri arasındaki ilişki(Van Yüzüncü Yıl Üniversitesi Tıp Fakültesi, 2022) Sezgin, Yasin; Karhan, Oğur; İleri, Serdar; Ebinç, Senar; Bilen, Erkan; Ürün, Muslih; Yerlikaya, HalisAmaç: Meme kanseri dünya çapında kadınlarda en sık görülen ve en sık ölüme yol açan kanserdir. Pozitron emisyon tomografisi (PET) - bilgisayarlı tomografinin (BT) onkolojide kullanımı giderek artan öneme sahip olmaktadır. Çalışmamızda tümörün bazı özelliklerine göre 18 F-floro-2-deoksi-D-glukoz ( 18 F-FDG) tutulum yoğunluğu arasındaki ilişkiyi araştırmayı planladık. Gereç ve Yöntem: Çalışmamızda onkoloji kliniğimize meme kanseri teşhisi ile başvuran ve PET-BT çekimi yapılan 414 hastanın dosyası retrospektif incelendi. Çalışmaya 18-90 yaş aralığında olan meme kanserli hastalar dahil edildi. İkincil malignitesi olan, akli dengesi yerinde olmayan, 18 yaşından küçük ve 90 yaşından büyük hastalar çalışma dışı bırakıldı. Moleküler alt tiplere, tümör boyutlarına, vücut kitle indeksine ve proliferasyon indekslerine göre FDG tutulumları araştırıldı. Bulgular: Çalışmaya dahil edilen 414 hastanın yaş ortalaması 48.8 yıldı. Hastaların büyük çoğunluğunun alt tipi; invaziv duktal karsinom idi. Tanı anında 86 hasta metastatik evrede iken, 327 hasta lokal veya lokal ileri evredeydi. Çalışmada Ki-67 artışı ile FDG tutulumunun artışı arasında korelasyon saptandı ve istatiksel olarak anlamlı bulundu. Sonuç: Çalışmada tümör boyutu büyük olanlarda daha fazla FDG tulumu mevcut idi. Aynı şekilde proliferasyon indeksi artışında ve invaziv duktal karsinomda daha yüksek FDG tutulumu mevcut idi. Tümör özellikleri ile FDG tutulumları arasındaki ilişki gelecekte bireyselleştirilmiş tedavi için prediktif bir belirteç olarak kullanılabilir.Öğe Prognostıc Factors In Testıcular Cancer(2024) Sezgin, Yasin; Karhan, Oğur; Biçer, Abdurrahman; İleri, Serdy; Yerlikaya, Halis; Tunç, Sezai; Aydın, İbrahimAim: Testicular cancer is the most common cancer in men aged 15-35 years and accounts for 1% of all lifetime male cancers. There are two histologic subtypes: seminoma and nonseminoma. In our study, we aimed to investigate the factors predicting recurrence in early-stage testicular cancer. Materials and Methods: Our study is a retrospective study of early stage testicular cancer admitted to the medical oncololi clinic of our hospital between 2006-2018. During the study, 344 patient files were reviewed and 130 patients who met the study criteria were included in the study. Our primary aim in this study was to investigate the factors predictive of recurrence in early stage testicular cancer. Results: When evaluating PFS in patients with nonseminoma with and without lymphovascular invasion, no median PFS value was reached in either group. However, PFS was worse in patients with LVI (p=0.037). When comparing stage 1 with stage 2 seminoma patients, no median PFS values could be reached, but there was a statistical difference between the two groups in terms of recurrence (p=0.019). Conclusions: In our study, we found no association between tumor size, embryonal carcinoma predominance, tunica albuginea invasion, spermatic cord involvement and tumor marker values and recurrence in nonseminoma germ cell testicular tumors. PFS was shorter in patients with LVI compared to those without LVI. Lymphovascular invasion, spermatic cord involvement, tunica albuginea involvement, and rete testis involvement were not associated with disease recurrence in seminoma patients, whereas higher disease stage predicted the risk of recurrence.Öğe Rare occurrence of synovial sarcoma originating from dura mater(Istanbul Tip Fakultesi, 2019) Akdeniz, Nadiye; Küçüköner, Mehmet; Kaplan, Muhammet Ali; Urakçı, Zuhat; Yerlikaya, Halis; Karhan, Oğur; Teke, Fatma; Işıkdoğan, AbdurrahmanPrimary or metastatic dura mater sarcomas are rarely seen, and dural synovial sarcomas are quite rare. Here we report the case of a 60-year-old man who presented with headache, nausea, and vomiting and was found to have a 63×33×40-mm mass with solid and cystic components in parieto-occipital lobe. The mass was resected completely, with no residue detected on postoperative magnetic resonance imagining. On pathological evaluation, a vimentin-, S100-, transducer-like enhancer of split 1-, BCL-2-, and EMApositive and desmin-, PR-, CD99-, PANCK-, and GFAP-negative synovial sarcoma with Ki-67 proliferation index of 12% was detected. Postoperatively, chemotherapy has been started, and it will be followed by radiotherapy. Primary meningeal-derived sarcomas are rare, and differential diagnosis with other meningeal mesenchymal tumors is based on the findings of morphological and immunohistochemical analyses.Öğe Real-life data of pazopanib usage inm soft tissue sarcoma(2023) İleri, Serdar; Yerlikaya, Halis; Ürün, Muslih; Sezgin, Yasin; Karhan, OğurAbstract: Objective: Soft tissue sarcomas are heterogeneous group of malignancies consisting of more than 50 subtypes. Although it is rare, it is usually resistant to chemotherapy and has a poor prognosis. In this study, we planned to investigate the efficacy, tolerability and side-effect profile of pazopanib in metastatic soft tissue sarcomas. Method-Material: Our study was a single-center retrospective study and included metastatic patients over the age of 18 who were treated with pazopanib. Data of 37 patients were obtained in retrospective medical records. In patients using pazopanib; Tumor location, histological subtype, tumor grade, disease stage, the line at which pazopanib was used, efficacy, tolerability, and side-effect profile of pazopanib were examined. Findings: The mean age of the patients at diagnosis was 49. Pleomorphic sarcoma was the most common subtype. The progression-free survival (PFS) of patients after first-line therapy was 18 weeks. The median overall survival (OS) of the patients was 20 months. The median PFS with pazopanip was 18 weeks. Conclusion: In the study we conducted research in terms of effectiveness and side effects; the use of pazopanib in soft tissue sarcoma was found to be effective in terms of both PFS and OS. Side effects were tolerable and treatable. In our study, a PFS of 32 weeks was obtained in patients with hypothyroidism and at 16 weeks in patients who did not. In this respect, development of hypothyroidism may be a predictive parameter for response.Öğe THE ROLE OF SERUM CARCINOEMBRYONIC ANTIGEN TO PREDICT RESPONSE OF TREATMENT IN NON-SMALL CELL LUNG CANCER PATIENTS Karsinoembriyonik Antijeninin Küçük Hücreli Dışı Akciğer Kanseri Hastalarında Tedavi Yanıtını Tahmin Etmedeki Rolü(Yozgat Bozok University, 2021) Akdeniz, Nadiye; Kaplan, Muhammet Ali; Küçüköner, Mehmet; Urakçı, Zuhat; Karhan, Oğur; Yerlikaya, Halis; Işıkdoğan, AbdurrahmanABSTRACT Objective: We aimed to determine tumor marker levels in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) at the time of diagnosis, to investigate the sensitivity and specificity of changes in Carcinoembryonic antigen (CEA) level in the assessment of treatment response along with the prognostic significance of this marker. Material and Methods: The study included 100 patients with NSCLC diagnosed in our institution. Age, stage, histologic subtype, tumor marker levels at the time of diagnosis, the change in serum CEA levels and the as-sociation with treatment response were analyzed. The treatment responses of the patients were evaluated either clinical response or progressive disease. Results: CEA level was stable or decreased in 86 (86%) clinical response, in contrary to elevation of CEA levels in 26 (74.3%) progressive response. The response to therapy and the change in CEA level were shown 86% ratio of sensitivity and 74.2% ratio of specificity in all patients regardless of baseline CEA levels. On the other hand, in patients with high baseline levels of CEA, sensitivity of the change in CEA level was 95% and specificity was 71.4%. Positive predictive value and negative predictive value were calculated as 90.5% and 65%, respectively. Conclusion: Change of CEA levels were associated with treatment response in patients with NSCLC. Given that it can be readily measured in serum samples, serum CEA level is a beneficial marker in follow-up and treatment response monitorization of these patients. The baseline level of CEA was not a prognostic factor. Keywords: Carcinoembryonic Antigen; Non-Small Cell Lung Cancer; Prognosis ÖZET Amaç: Lokal ileri veya metastatik küçük hücreli dışı akciğer kanseri (KHDAK) tanılı hastalarda tanı anında tümör belirteç düzeylerini belirlemeyi, tedavi yanıtının değerlendirilmesinde Karsinoembriyonik antijen (CEA) düzeyindeki değişikliklerin duyarlılığını ve özgüllüğünü prognostik önemi ile birlikte değerlendirmeyi amaçladık. Gereç ve Yöntemler: Çalışmaya 100 KHDAK tanılı hasta dahil edildi. Tanı anındaki yaş, evre, histolojik alt tip, tümör belirteçleri, serum CEA seviyelerindeki değişim ve tedavi yanıtı ile ilişkisi analiz edildi. Hastaların tedavi yanıtları, klinik yanıt alındı veya alınmadı şeklinde değerlendirildi. Bulgular: CEA düzeyi 26 (%74,3) progresif yanıtta yükselmesine karşın 86 (%86) klinik yanıtta stabil veya azalmıştı. Tedaviye yanıt ve CEA düzeyindeki değişiklik, başlangıç CEA düzeylerinden bağımsız olarak tüm hastalarda %86 duyarlılık oranı ve %74,2 özgüllük oranı göstermekteydi. Öte yandan, CEA başlangıç düzeyi yüksek olan hastalarda, CEA düzeyindeki değişikliğin duyarlılığı %95 ve özgüllüğü %71,4 idi. Pozitif prediktif değer ve negatif prediktif değer sırasıyla %90,5 ve %65 olarak hesaplandı. Sonuç: KHDAK hastalarında CEA düzeylerindeki değişiklik tedavi yanıtı ile ilişkilendirilmiştir. Serum örnekle-rinde kolaylıkla ölçülebildiği düşünüldüğünde, serum CEA düzeyi bu hastaların takip ve tedaviye yanıt moni-törizasyonunda yararlı bir belirteçtir. CEA'nın başlangıç seviyesi prognostik bir faktör olarak belirlenmemiştir. Anahtar Kelimeler: Karsinoembriyonik Antijen; Küçük Hücreli Dışı Akciğer Kanseri; PrognozÖğe Two malignant mesothelioma cases with brain metastasis(Akademi Doktorlar Yayınevi, 2017) Oruç, Zeynep; Kaplan, Muhammet Ali; Oruç, İdris; Urakçı, Zuhat; Yerlikaya, Halis; Küçüköner, Mehmet; Işıkdoğan, AbdurrahmanA 32-year-old male patient presented to our clinic in February 2014 with complaints of chest pain and dyspnea, which lasted for the last six months. In the xray examination,the right sinus was closed and there was the pleural effusion (Figure 1).
